Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum

Patients with indolent conjunctival lymphomas exhibit good prognosis, with exceptional cases of dissemination, and are suitable candidates for intralesional therapies. We report the first prospective phase 2 trial using intralesional rituximab supplemented with autologous serum in adults with relaps...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Adv
Autors principals: Ferreri, Andrés J. M., Sassone, Marianna, Miserocchi, Elisabetta, Govi, Silvia, Cecchetti, Caterina, Corti, Matteo E., Mappa, Silvia, Arcaini, Luca, Zaja, Francesco, Todeschini, Giuseppe, Mannina, Donato, Calimeri, Teresa, Perrone, Salvatore, Ponzoni, Maurilio, Modorati, Giulio
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7094013/
https://ncbi.nlm.nih.gov/pubmed/32182364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001459
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars